natgillin/translations-raw huggingface dataset:
The individual half-lives varied from 4.4 to 15.8 hours using a compartmental model and from 4.9 to 14.7 using the non-compartmental method.
Razpolovne dobe pri posameznikih so se gibale od 4,4 do 15,8 ur pri uporabi razdelčnega (t.j. kompartmentalnega) modela in od 4,9 do 14,7 pri uporabi nerazdelčnega.
The individual patient dose =
Odmerek za bolnika =
The individual preparations of abacavir and lamivudine have been investigated separately, and as a dual nucleoside backbone, in combination antiretroviral therapy to treat ART- naive and ART- experienced HIV- infected paediatric patients (data available on the use of abacavir and lamivudine in infants less than three months are limited).
Posamezna zdravila abakavirja in lamivudina so raziskovali posebej, in kot dvojno nukleozidno osnovo, v kombinaciji s protiretrovirusno terapijo za zdravljenje s HIV okuženimi pediatričnimi bolniki, ki predhodno še niso ali so že prejemali ART (razpoložljivi podatki o uporabi abakavirja in lamivudina pri dojenčkih, mlajših od treh mesecev, so omejeni).
The individualised prophylaxis dose and interval were adjusted between the range of 25 to 65 IU/kg every 3 to 5 days.
Individualizirani profilaktični odmerek in interval sta bila prilagojena v razponu od 25 do 65 i.e./kg vsakih 3 do 5 dni.
The induced QRS interval prolongation from 6 ms to 9.5 ms with high dose lopinavir/ritonavir (800/200 mg twice daily) contributes to QT prolongation.
K podaljšanju intervala QT pripomore podaljšanje intervala QRS s 6 ms na 9,5 ms, ki ga povzročijo veliki odmerki lopinavirja/ritonavirja (800 mg/200 mg dvakrat na dan).
The induced QRS interval prolongation from 6 ms to 9.5 ms with high dose lopinavir/ritonavir (800/200 mg twice daily) contributes to QT prolongation.
K podaljšanju intervala QT pripomore podaljšanje intervala QRS s 6 ms na 9,5 ms, ki ga povzročijo veliki odmerki lopinavirja/ritonavirja (800/200 mg dvakrat na dan).
The inducing effect may persist for at least 2 weeks after cessation of treatment with St John’s wort (see section 4.3).
Inducirajoči učinek lahko vztraja še najmanj 2 tedna po opustitvi zdravljenja s pripravki iz šentjanževke (glejte poglavje 4.3).
The inducing effect may persist for at least 2 weeks after cessation of treatment with St John’s wort (see section 4.3).
Indukcijski učinek lahko traja še vsaj 2 tedna po opustitvi šentjanževke (glejte poglavje 4.3).
The inducing effect may persist for at least 2 weeks after cessation of treatment with St John’s wort (see section 4.3).
Indukcijski učinek lahko traja še vsaj 2 tedna po prenehanju zdravljenja s šentjanževko (glejte poglavje 4.3).
The inducing effect may persist for at least 2 weeks after cessation of treatment with St John’s wort.
Inducirajoči učinek lahko vztraja še najmanj 2 tedna po opustitvi zdravljenja s pripravki iz šentjanževke.
The inducing effect may persist for at least 2 weeks after cessation of treatment with St John’s wort.
Inducirajoči učinek lahko vztraja še najmanj 2 tedna po opustitvi zdravljenja s pripravki, ki vsebujejo šentjanževko.
The inducing effect may persist for at least 2 weeks after cessation of treatment with St John’s wort.
Učinek indukcije encimov je lahko prisoten še vsaj 2 tedna po prekinitvi zdravljenja s šentjanževko.
The inducing effect of St. John’s wort may persist for at least 2 weeks after cessation of treatment (see section 4.3).
Induktivni učinek šentjanževke lahko traja vsaj še 2 tedna po prekinitvi zdravljenja (glejte poglavje 4.3).
The inducing effect of St. John’s wort may persist for at least 2 weeks after cessation of treatment (see section 4.3).
Induktivni učinek šentjanževke lahko traja vsaj še 2 tedna po prenehanju zdravljenja (glejte poglavje 4.3).
The inducing effect of St. John’s wort may persist for at least 2 weeks after cessation of treatment.
Inducirajoči učinek šentjanževke lahko traja še vsaj 2 tedna po prekinitvi zdravljenja.
The inducing effect of St. John’s wort may persist for at least 2 weeks after cessation of treatment.
Induktivni učinek šentjanževke na encime lahko traja vsaj še 2 tedna po prekinitvi zdravljenja s šentjanževko.
The inducing effect of St. John’s wort may persist for at least 2 weeks after cessation of treatment. (see section 4.3).
Induktivni učinek šentjanževke lahko traja vsaj še 2 tedna po prenehanju zdravljenja (glejte poglavje 4.3).
The infant adverse reactions were in the range of normal variation and were comparable with both placebo and beta- mimetic group incidences.
Neželeni učinki pri dojenčkih so bili v območju normalnih variacij in po pogostnosti primerljivi s tistimi v skupini, ki je prejemala placebo in v skupini, ki je prejemala beta-mimetik.
The infants were followed for up to 3 years post-vaccination in the FES.
Dojenčke so v FES spremljali 3 leta po cepljenju.
The infection of piglets occurs mostly during the first 6 weeks of life, when the immune system of piglets is still maturing.
Do okužbe pujskov pride večinoma v prvih šestih tednih življenja, ko njihov imunski sistem šele dozoreva.
The infection was considered to have responded to treatment if the viral load in the patient’s blood was less than 50 of HIV-1 RNA copies/ml.
Za okužbo je veljalo, da se je odzvala na zdravljenje, če je bila virusna obremenitev v bolnikovi krvi manjša od 50 HIV-1 RNA kopij/ml.
The infections observed most commonly with sunitinib treatment are infections typically seen in cancer patients, e.g. respiratory, urinary tract, skin infections and sepsis.
Pri zdravljenju s sunitinibom so najpogosteje opažene okužbe tiste, ki se običajno pojavljajo pri bolnikih z rakom, kot na primer okužbe dihal, sečil, kože in sepsa.
The infections resolved without sequelae.
Okužbe so izzvenele brez posledic.
The influence of East Asian ethnicity on the pharmacokinetics of eltrombopag was evaluated using a population pharmacokinetic analysis in 111 healthy adults (31 East Asians) and 88 patients with ITP (18 East Asians).
Vpliv vzhodnoazijskega porekla na farmakokinetiko eltrombopaga je bil ovrednoten z analizo populacijske farmakokinetike pri 111 zdravih odraslih osebah (31 oseb vzhodnoazijskega porekla) in 88 bolnikih z ITP (18 bolnikov vzhodnoazijskega porekla).
The influence of liver impairment on the pharmacokinetics of sitaxentan sodium has not been evaluated.
Vpliv okvare jeter na farmakokinetiko natrijevega sitaksentanata ni raziskan.
The influence of race on icatibant pharmacokinetics has not been evaluated.
Vpliva rase na farmakokinetične lastnosti ikatibanta niso preučevali.
The influence of renal impairment on exposure to porfimer sodium has not been evaluated (see section 4.3).
Vpliv ledvične okvare na izpostavljenost porfimer-natriju ni bil ocenjen (glejte poglavje 4.3).
The influence of renal impairment on exposure to porfimer sodium has not been evaluated. (see section 4.3).
Vpliv ledvične okvare na izpostavljenost PhotoBarru ni bil ocenjen (glejte poglavje 4.3).
The influence of the P-gp inhibitor verapamil on the pharmacokinetics of subcutaneous pasireotide was tested in a drug-drug interaction study in healthy volunteers.
Učinek verapamila, ki je zaviralec P-gp (P-glikoproteina), na farmakokinetiko subkutano apliciranega pasireotida so preverjali v študiji medsebojnega delovanja zdravil na zdravih prostovoljcih.
The influence on fertility in male breeding dogs has not been studied.
Učinek na plodnost pri plemenskih samcih ni raziskan.
The influenza virus strain in Pandemic influenza vaccine H5N1 MedImmune is (a) cold-adapted (ca); (b) temperature-sensitive (ts); and (c) attenuated (att).
Sev virusa gripe v Cepivu proti pandemski gripi H5N1 MedImmune je (a) prilagojen hladu (cold- adapted – ca), (b) občutljiv na temperaturo (temperature-sensitive – ts) in (c) oslabljen (attenuated – att).
The information card will remind prescribers how to use the medicine safely.
Kartica z informacijami pa bo zdravnike, ki zdravilo predpisujejo, opominjala, kako ga varno uporabljati.
The information collected should include:
Zbrani podatki morajo obsegati:
The Information for healthcare professionals should contain the following key elements:
Informacije za zdravstvene delavce morajo vsebovati naslednje ključne sestavine:
The information for male partners of women with child-bearing potential should include the following information:
Informacije za moške partnerje žensk v rodni dobi morajo vključevati naslednje:
The information for patients should include the following information:
Informacije za bolnike morajo vključevati naslednje:
The information from these studies was compared to published reports describing the outcome of untreated patients with the disease.
Informacije iz teh študij so bile primerjane z objavljenimi poročili, ki opisujejo izid pri nezdravljenih bolnikih s to boleznijo.
The information in this leaflet applies to all patient groups including children, adolescents, adults and the elderly.
Informacija na teh navodilih za uporabo se nanaša na vse skupine bolnikov, vključno z otroci, mladostniki, odraslimi in starejšimi.
The information presented was not sufficient to support the use of Dukoral in traveller’s diarrhoea.
Predstavljeni podatki niso bili zadostni, da bi bilo mogoče podpreti uporabo cepiva Dukoral za popotniško drisko.
The information provided regarding the signal of local amyloidosis gives evidence based on two well documented cases that enfuvirtide as a peptide can cause cutaneous amyloidosis at the injection site.
Pridobljene informacije glede signala lokalne amiloidoze temeljijo na dveh dobro dokumentiranih primerih in dokazujejo, da enfuvirtid kot peptid lahko povzroči kožno amiloidozo na mestu injiciranja.
The information reported in the Table mostly derives from in vitro studies.
Podatki, navedeni v preglednici, večinoma izvirajo iz študij in vitro.
The infrared radiation in the measuring chamber is weakened by the gas component to be measured.
Ta plinska komponenta oslabi infrardeče žarčenje v merilni komori.
The infusion bag containing diluted KRYSTEXXA should not be shaken.
Infuzijska vrečka, ki vsebuje razredčeno zdravilo KRYSTEXXA, se ne sme pretresti.
The infusion bag containing the diluted KRYSTEXXA solution should be inverted a number of times gently to ensure thorough mixing.
Infuzijsko vrečko z razredčeno raztopino zdravila KRYSTEXXA je treba večkrat nežno obrniti, da se zagotovi temeljito mešanje.
the infusion bag empties before the scheduled bag change if the infusion pump stops unexpectedly.
e infuzijska vrečka izprazni pred časom, ki je predviden za zamenjavo vrečke. se infuzijska črpalka nepričakovano ustavi.
The infusion bag must be changed at least every 96 hours by a health care professional for sterility reasons.
Infuzijsko vrečko je treba zamenjati vsaj na 96 ur; zaradi sterilnosti jo mora zamenjati zdravstveni delavec.
The infusion bag solution should be used within 6 hours below 25 °C and normal lighting conditions including the one hour infusion to the patient.
Raztopino za infundiranje v infuzijski vrečki je treba uporabiti v 6 urah na temperaturi do 25°C in pri normalnih pogojih osvetljenosti, to vključuje tudi 1 uro infundiranja bolniku .
The infusion bag solution should be used within 6 hours below 25°C including the one hour infusion to the patient.
Raztopino za infundiranje v infuzijski vrečki je treba uporabiti v 4 urah na temperaturi do 25°C, to vključuje tudi 1 uro infundiranja bolniku.
The infusion bags(s) is/are placed inside a closed outer container.
Infuzijska vrečka/infuzijske vrečke je/so položena/položene v zaprt zunanji vsebnik.
The infusion can be restarted with a reduction of the infusion rate to 1/2 – 1/4 the rate of the infusion at which the reaction occurred.
V nadaljevanju lahko dajete bolniku infuzijo s hitrostjo, ki je za četrtino do polovico manjša od hitrosti, ob kateri je prišlo do reakcije.
The infusion can be restarted with a reduction of the infusion rate to 50% – 25% of the rate at which the reaction occurred.
Po končani prekinitvi infuzije je treba njeno hitrost zmanjšati na 50% do 25% hitrosti, pri kateri se je reakcija pojavila.
The infusion duration should not exceed 2 hours.
Infuzija naj ne traja več kot dve uri.
The infusion duration should not exceed 2 hours.
Trajanje infundiranja ne sme preseči 2 ur.
The infusion flow rate should be controlled to equate to a 2 hour period of administration.
Hitrost infuzije je treba uravnati tako, da boste infuzijo prejeli v 2 urah.
The infusion is given at a recommended dose of 2 mg per kilogram body weight over 30 minutes every three weeks.
Infuzija se daje s priporočenim odmerkom 2 mg na kilogram telesne mase v 30 minutah vsake tri tedne.
The infusion is given slowly over at least 2 hours.
Infuzija se daje počasi v trajanju najmanj dveh ur.
The infusion is given to you every 3 weeks, although occasionally your doctor may recommend dose delays to ensure that you receive the most appropriate dose of Yondelis.
Infuzijo boste prejeli vsake 3 tedne, vendar pa lahko vaš zdravnik včasih odmerek prestavi in zagotovi, da boste prejeli najustreznejši odmerek zdravila Yondelis.
The infusion lasts 20 to 30 minutes.
Infundiranje traja 20 do 30 minut.
The infusion lasts at least one hour and the dose depends on the patient’s bodyweight.
Infundiranje traja najmanj eno uro, odmerek pa je odvisen od bolnikove telesne mase.
The infusion may be followed by an infusion at a lower dose of 0.25 mg/kg body weight for an additional 4 to 12 hours.
Infuziji lahko sledi infuzija z manjšim odmerkom 0,25 mg/kg telesne mase, ki traja še 4–12 ur.
The infusion may then be resumed at a slower rate (up to 60 minutes) and should be completed within six hours from the time that Torisel is first added to sodium chloride 9 mg/ml (0.9%) solution for injection.
Nato se sme infuzija z manjšo hitrostjo (do 60 minut) ponovno začeti in se mora končati najpozneje šest ur po tistem, ko je bilo zdravilo Torisel v začetku dodano raztopini natrijevega klorida 9 mg/ml (0,9 %) za injiciranje.
The infusion must be administered at constant rate with duration time of at least 3 hours.
Infuzijo se mora dajati s stalno hitrostjo s trajanjem infuzije vsaj 3 ure.
The infusion must be administered through a sterile, non-pyrogenic, low protein binding in-line filter with a pore size of 0.2-1.2 m.
Zdravilo je treba infundirati preko sterilnega, nepirogenega linijskega filtra, ki minimalno veže proteine, z velikostjo por od 0,2 do 1,2 μm.
The infusion must be conducted according to standard medical practice.
Postopek infundiranja morate opraviti v skladu s standardno medicinsko prakso .
The infusion must be stopped and therapy permanently discontinued if the patient experiences a second occurrence of a Grade 3 IRR.
Infundiranje je treba ustaviti in zdravljenje trajno končati, če se pri bolniku še drugič pojavi z infuzijo povezana reakcija 3. stopnje.
The infusion of 1.75 mg/kg body weight/hour may be continued for up to 4 hours post-PCI and at a reduced dose of 0.25 mg/kg body weight/hour for an additional 4 – 12 hours as clinically necessary.
Infundiranje 1,75 mg/kg telesne mase/h se lahko nadaljuje še največ 4 ure po PCI in nato še, v skladu s kliničnimi potrebami, 4–12 ur z infundiranjem zmanjšanega odmerka 0,25 mg/kg/h.
The infusion of 1.75 mg/kg body weight/hour may be continued for up to 4 hours post-PCI and at a reduced dose of 0.25 mg/kg body weight/hour for an additional 4 – 12 hours as clinically necessary.
Infundiranje 1,75 mg/kg telesne mase/h se lahko nadaljuje še največ 4 ure po PCI in nato še, v skladu s kliničnimi potrebami, 4–12 ur z zmanjšanim odmerkom 0,25 mg/ telesne mase /h.
The infusion rate can continue to be increased according to standard procedures, according to physician discretion and patient tolerance (not to exceed increasing the rate every 30 minutes).
Hitrost infundiranja je mogoče še naprej povečevati v skladu s standardnimi postopki, upoštevaje zdravnikovo presojo in bolnikovo prenašanje (hitrosti se ne sme povečevati na manj kot vsakih 30 minut).
The infusion rate may be increased gradually with further infusions.
Da se izognemo neželenim učinkom, povezanih z infuzijo, začetna hitrost infundiranja ne sme
The infusion rate may be slowed or interrupted if the patient develops an infusion reaction (see section 4.8).
Če se razvije infuzijska reakcija, se hitrost infuzije upočasni ali infundiranje prekine (glejte poglavje 4.8).
The infusion rate should be reduced when re-starting the infusion (see section 4.2).
Pri ponovni uvedbi infuzije je treba začeti z zmanjšano hitrostjo infundiranja (glejte poglavje 4.2).
The infusion rate will be increased every 15 minutes as follows: first increase the rate to 12 ml/hr, then increase the rate every 15 minutes by 12 ml/hr increments until a maximum rate of
Hitrost infundiranja povečajte vsakih 15 minut, in sicer jo najprej povečajte na 12 ml/uro in nato vsakih 15 minut v korakih po 12 ml/uro, dokler ne dosežete največje hitrosti
The infusion schedule is 8 consecutive weekly infusions, followed 4-5 weeks later by 4 consecutive monthly (i.e. every 4 weeks) infusions.
Časovni razpored infundiranj je: 8 zaporednih tedenskih infundiranj, ki jim od 4 do 5 tednov pozneje sledijo 4 zaporedna mesečna infundiranja (tj. vsake 4 tedne).
The infusion set should be changed every 48 hours using aseptic technique when inserting the infusion set.
Infuzijski komplet je treba zamenjati na 48 ur; pri vstavljanju infuzijskega kompleta je treba uporabljati asepticen postopek.
The infusion sets should be made of one of the following materials: polyvinyl chloride (PVC) containing bis(2-ethylhexyl) phthalate (DEHP)
Kompleti za infundiranje naj bodo izdelani iz enega od naslednjih materialov: polivinilklorida (PVC), ki vsebuje bis(2-etilheksil)ftalat (DEHP)
The infusion should be discontinued immediately if the patient experiences a NCI-CTCAE Grade 4 reaction (anaphylaxis), bronchospasm or acute respiratory distress syndrome (see section 4.4).
Infundiranje je treba nemudoma prekiniti, če se razvije reakcija stopnje 4 po merilih NCI-CTCAE (anafilaksija), bronhospazem ali akutni respiratorni distresni sindrom (glejte poglavje 4.4).
The infusion should last
Infuzija mora trajati približno 4 ure.
The infusion should last 1 hour.
Infundiranje traja eno uro.
The infusion should last 30 minutes.
Infuzija naj traja 30 minut.
The infusion solution concentration during preparation and administration should not exceed 12 mg/ml ceftaroline fosamil.
Koncentracija raztopine za infundiranje med pripravo in dajanjem ne sme presegati 12 mg/ml fosamilceftarolina.
The infusion solution contains approximately 1.5 mg/mL isavuconazonium sulfate (corresponding to approximately 0.8 mg isavuconazole per mL).
Infuzijska raztopina vsebuje pribliţno 1,5 mg/ml izavukonazonijevega sulfata (kar ustreza pribliţno 0,8 mg izavukonazola na ml).
The infusion solution is normally given over about 15 minutes (about 0.08 ml of solution per kg body weight each min).
Raztopina se običajno infundira 15 minut (približno 0,08 ml raztopine na kg telesne mase vsako minuto).
The infusion solution must not be coupled to the infusion set for more than 8 h at 25C.
Raztopina za infundiranje ne sme biti priključena na infuzijski set dlje kot 8 ur pri temperaturi do 25°C
The infusion solution must not be coupled to the infusion set for more than 8 h at 25C.
Raztopina za infundiranje ne sme biti priključena na infuzijski set dlje kot 8 ur pri temperaturi do 25°C.
The infusion solution should be prepared using aseptic technique to ensure the sterility of the prepared solution.
Raztopino za infundiranje je treba pripraviti aseptično, da boste zagotovili sterilnost pripravljene raztopine.
The infusion speed of the perfusor automate is to be set in a body weight-dependent fashion (see section 4.2).
Infuzijsko hitrost avtomatskega perfuzorja naravnamo v skladu s telesno maso bolnika (glejte poglavje 4.2).
The infusion speed of the perfusor automate is to be set in a body weight-dependent fashion.
Infuzijsko hitrost avtomatskega perfuzorja naravnamo v skladu s telesno maso bolnika.
The infusion time is 1 hour for 1 g / 0.5 g of Zerbaxa.
Čas infundiranja 1 g/0,5 g zdravila Zerbaxa je 1 ura.
The infusion will be given to you, by your doctor or nurse, through a drip in one of the veins in your arm (intravenous infusion) over about 30 minutes.
Infuzijo zdravila vam bo dal zdravnik ali medicinska sestra v obliki 30-minutne kapljične infuzije v eno od ven na roki (intravenska infuzija).
The ingested dose was 40 times the recommended dose of 2 mg/kg/day.
Zaužiti odmerek je bil 40- krat večji od priporočenega odmerka, ki je 2 mg/kg na dan.
The ingredient in the solvent is sodium chloride 9 mg/ml.
Vehikel vsebuje raztopino natrijevega klorida (9 mg/ml).
The ingredients in the film-coating are glycerol (85 per cent) (E422), hypromellose, magnesium stearate, polysorbate 80, red iron oxide (E172), sucrose and titanium dioxide (E171).
Sestavine v filmski oblogi so: glicerol (85 odstotkov) (E422), hipromeloza, magnezijev stearat, polisorbat 80, rdeči železov oksid (E172), saharoza in titanov dioksid (E171).
The ingredients in the film-coating are glycerol (85 per cent) (E422), hypromellose, magnesium stearate, polysorbate 80, red iron oxide (E172), sucrose, and titanium dioxide (E171).
Sestavine v filmski oblogi so: glicerol (85 odstotkov) (E422), hipromeloza, magnezijev stearat, polisorbat 80, rdeči železov oksid (E172), saharoza in titanov dioksid (E171).
The ingredients in the film-coating are glycerol (85 per cent) (E422), hypromellose, magnesium stearate, polysorbate 80, red iron oxide (E172), sucrose, titanium dioxide (E171), and yellow iron oxide (E172).
Sestavine v filmski oblogi so: glicerol (85 odstotkov) (E422), hipromeloza, magnezijev stearat, polisorbat 80, rdeči železov oksid (E172), saharoza, titanov dioksid (E171) in rumeni železov oksid (E172).
The ingredients of the capsule shell are gelatin, sorbitol sorbitan solution (see section 2), glycerol, titanium dioxide (E171), and purified water.
Sestavine ovojnice kapsule so želatina, sorbitol in raztopina sorbitanov (glejte poglavje 2), glicerol, titanov dioksid (E171) in prečiščena voda.
The ingredients of the ink are iron oxide black (E172) and polyvinyl acetate phthalate.
Sestavini črnila sta črni železov oksid (E172) in polivinilacetatftalat.
The inhaler contains two aluminium foil laminate strips of 14 or 30 doses.
V notranjosti inhalatorja se nahajata dva laminatna trakova iz aluminija s 14 ali 30 odmerki.
The inhaler delivers 22 micrograms of vilanterol and 55 micrograms of umeclidinium (as umeclidinium bromide) with each inhalation.
Inhalator pri vsaki inhalaciji sprosti 22 mikrogramov vilanterola in 55 mikrogramov umeklidinija (v obliki umeklidinijevega bromida).
The inhaler delivers 22 micrograms of vilanterol and 65 micrograms of umeclidinium bromide (equivalent to 55 micrograms of umeclidinium) with each inhalation.
Inhalator z vsako inhalacijo dovede 22 mikrogramov vilanterola in 65 mikrogramov umeklidinijevega bromida, kar ustreza 55 mikrogramom umeklidinija.
The inhaler delivers 375 micrograms of aclidinium bromide equivalent to 322 micrograms of aclidinium for each inhalation.
Inhalator dovede 375 mikrogramov aklinidijevega bromida, kar ustreza 322 mikrogramom aklidinija.
The inhaler delivers 65 micrograms of umeclidinium bromide equivalent to
Inhalator dovede 65 mikrogramov umeklinidijevega bromida, kar ustreza
The inhaler device is a multicomponent device made of polycarbonate, acrylonitrile-butadiene- styrene, polyoxymethylene, polyester-butylene-terephthalate, polypropylene, polystyrene and stainless steel.
Inhalacijski pripomoček sestavlja več kosov iz polikarbonata, akrilonitril-butadien-stirena, polioksimetilena, poliester-butilen-tereftalata, polipropilena, polistirena in nerjavnega jekla.
The inhaler is a multi-component device composed of polypropylene, high density polyethylene, polyoxymethylene, polybutylene terephthalate, acrylonitrile butadiene styrene, polycarbonate and stainless steel.
Inhalator je večdelni pripomoček iz polipropilena, polietilena velike gostote, polioksimetilena, polibutilentereftalata, akrilonitril butadienstirena, polikarbonata in nerjavečega jekla.
The inhaler is made of acrylonitrile butadiene styrene (ABS), polyethylene terephthalate (PT) , and polypropylene (PP).
Inhalator je izdelan iz akrilnitril- butadien-stirena (ABS), polietilen tereftalata (PT) in polipropilena (PP).